Clinical Trials Logo

Clinical Trial Summary

The diagnosis of secondary hypoadrenalism and GH deficiency (GHD) often requires the performance of a dynamic test. The glucagon stimulation test (GST) is one of the options for evaluating hypothalamic-pituitary function, representing a stimulus for both the corticotropic and somatotropic axis, substantially safe and easily available. The standard procedure involves the intramuscular injection of 1-1.5 mg of glucagon based on the patient's weight. In addition to its antero-pituitary function, glucagon has also shown its ability to stimulate neurohypophyseal secretion. Using the copeptin dosage, it has been shown that after the administration of glucagon in healthy subjects there is a significant release of ADH. However, the available data are scarse and there is no standardized protocol for the use of the glucagon test in diabetes insipidus. At the moment, GST is not the most frequently chosen diagnostic option. In fact, despite having the advantage of being able to investigate different areas of anterohypophyseal and probably posterohypophyseal function at the same time, the test has some disadvantages: the prolonged duration makes the procedure challenging, the intramuscular injection can be unwelcome, and many variables can come into play in the definition of a normal response (age, BMI, glycemic status). The recent introduction of a single-dose nasal powder formulation (Baqsimi®) could overcome some of the limitations of classic GST and make the procedure less demanding. To date, no assessments are yet available regarding a purely diagnostic role in the context of hypopituitarism of this new formulation. Through the knowledge of the physiological response of the adrenocortical, somatotropic and ADH axis to the administration of intranasal glucagon in healthy subjects, it will be possible to evaluate its possible application in the diagnosis of GH deficiency, central adrenal insufficiency and possibly diabetes insipidus.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05206149
Study type Interventional
Source Azienda Ospedaliera Città della Salute e della Scienza di Torino
Contact
Status Completed
Phase Phase 4
Start date October 1, 2021
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02871986 - Pubertal Induction in Individuals With Hypogonadism N/A
Completed NCT00851942 - Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Phase 4
Completed NCT00507104 - Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
Completed NCT01088399 - A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults N/A
Completed NCT00027430 - Androgen Replacement Therapy in Women With Hypopituitarism N/A
Recruiting NCT04897802 - Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) Phase 4
Recruiting NCT04121780 - Growth Hormone Replacement Therapy for Retried Professional Football Players Phase 2
Not yet recruiting NCT01666964 - Hormone Deficiency After Brain Injury During Combat N/A
Completed NCT01028742 - Posttraumatic Hypopituitarism - Incidence, Predictors and Test Validity N/A
Completed NCT00139945 - Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients N/A
Completed NCT05188131 - Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium Phase 4
Completed NCT00133354 - Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys Phase 2/Phase 3
Not yet recruiting NCT03708523 - Next Day Growth Hormone Predicting Pituitary Function After Adenomectomy
Completed NCT01007071 - Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency Phase 3
Completed NCT00080483 - Testosterone and Growth Hormone for Bone Loss in Men Phase 2
Completed NCT01009905 - An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone) N/A
Completed NCT01209416 - The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin N/A
Recruiting NCT04902235 - Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study) Phase 4
Terminated NCT00504218 - Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients
Terminated NCT02360046 - The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism N/A